SEC Form 4 · accession 0001213900-15-001592
RELMADA THERAPEUTICS, INC. · RLMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sergio Traversa
Officer — Chief Executive Officer · Director
Period of report
Feb 23, 2015
Accepted (ET)
Mar 5, 2015 · 5:17 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001553643
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to purchase common stockF2,F1 | $2.70 | Feb 23, 2015 | A | 225,000 | A | — | Feb 23, 2025 | Common stock | 225,000 | 872,745 | D |
Explanation of responses
- F1Pursuant to the terms of the company's 2014 Stock Option and Equity Incentive Plan, 6.25% of the options shall vest each quarter from the date of grant.
- F2. Includes (i) options to purchase an aggregate of 677,962 shares of Common Stock of the Company, 519,065 shares of Common Stock will have vested within 60 days of March 5, 2015, (ii) options to purchase an aggregate of 665,750 shares of Common Stock of the Company, 353,680 shares of Common Stock will have vested within 60 days of March 5, 2015, and (iii) options to purchase an aggregate of 225,000 shares of Common Stock of the Company, 0 shares of Common Stock will have vested within 60 days of March 2, 2015.